Evidence-Based Answers

Evidence Central™ is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research.

Browse

Evidence Central for Mobile Devices

Evidence Central iOS iPhone iPad Android

Evidence Central from Unbound Medicine, available for iOS® and Android™, is optimized for each platform and features superior navigation, so answers are easy to find at the bedside or anywhere they’re needed. Learn More

Word of the Day

Sildenafil does not improve outcomes in adults with heart failure and preserved EF

Clinical Question:
Is the phosphodiesterase-5 inhibitor sildenafil effective in reducing morbidity and/or mortality in adults with heart failure with preserved ejection fraction?

Bottom Line:
In this study, phosphodiesterase-5 inhibition with sildenafil did not significantly improve outcomes in adults with heart failure with preserved ejection fraction. (LOE = 1b-)

Reference:
Redfield MM, Chen HH, Borlaug BA, et al, for the RELAX trial. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction. A randomized clinical trial. JAMA 2013;309(12):1268-1277.  [PMID:23478662]

Study Design:
Randomized controlled trial (double-blinded)

Funding:
Industry + govt

Allocation:
Uncertain

Setting:
Outpatient (any)

Synopsis:
Inhibition of phosphodiesterase-5 reduces cardiac structural and functional dysfunction. These investigators identified 216 stable outpatients (median age = 69 years) who met standard clinical and laboratory criteria for heart failure with preserved (greater than or equal to 50%) ejection fraction. Eligible patients randomly received (uncertain allocation concealment) either sildenafil or matched placebo. The study drug was initially administered orally: 20 mg 3 times daily for 12 weeks, with a dose increase to 60 mg 3 times daily for an additional 12 weeks, if tolerated. Individuals masked to treatment group assignment assessed outcomes. Complete follow-up occurred for 92% of participants at 24 weeks. Using intention-to-treat analysis, sildenafil did not significantly improve peak oxygen consumption or 6-minute walking distance compared with placebo. In addition, sildenafil did not significantly reduce hospitalizations, heart failure symptoms, or overall mortality. There were also no significant differences between the 2 groups in adverse events. The study was 85% powered to detect a predetermined relevant difference between the 2 groups.

RSS FEED

Site Licenses

Site license

Site Licenses are available for schools, universities, hospitals, government agencies, and companies. For more information, contact us.